Close Menu

For a Good Cause

23andme is expanding its 23andWe initiative, which aims to acquire detailed health and trait data from existing customers, by recruiting 10,000 Parkinson's disease patients for a targeted analysis of the genetic and environmental causes of this disease. The program, backed in part by the Michael J. Fox Foundation, was announced on the 23andMe blog. Parkinson's patients get access to the full features of a 23andMe genome scan for $25 in return for participation in online surveys.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.